Catalog No.: PC-24962Not For Human Use, Lab Use Only.
KL1333 (Napazimone) is an orally available, small molecule NAD+ modulator, reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation.
KL1333 (Napazimone) is an orally available, small molecule NAD+ modulator, reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation. KL1333 is significantly more active and potent than idebenone and CoQ10. KL1333 increases the intracellular NAD+/NADH ratio, in C2C12 mouse myoblasts, L6 rat myoblasts, and HepG2 human hepatocarcinoma cells, which could be blocked by the NQO1-specific inhibitor ES936. KL1333 activates SIRT1 and AMPK in a NQO1-dependent manner, induces PGC-1α activation in C2C12 myoblasts. KL1333 (1 uM) regulates intracellular ATP, lactate, and ROS levels, increases the NAD+/NADH ratio and activates SIRT1, AMPK, and PGC-1α in MELAS fibroblasts. KL1333 is an activator of the SIRT1/AMPK/PGC-1α signaling network.
Physicochemical Properties
M.Wt
240.26
Formula
C14H12N2O2
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
2-isopropyl-1H-naphtho[1,2-d]imidazole-4,5-dione
References
1. Seo KS, et al. Front Neurol. 2018 Jul 5;9:552.
2. Lee HS, et al. Biomed Pharmacother. 2020 Jun;126:110068.
